The Association of Public Health Laboratories (APHL), in cooperation with the US Centers for Disease Control and Prevention (CDC) Division of Tuberculosis Elimination (DTBE), is seeking to award one-time funding for up to 20 state or local public health laboratories (PHLs) for the purpose of enhancing capacity for drug susceptibility testing (DST) of Mycobacterium tuberculosis (MTB), specifically with respect to fluoroquinolones (FQ) and rifampin (RIF). Funding will be awarded via a contract with APHL. ​

Eligibility ​

All state or local US public health laboratories that currently perform first-line pDST for MTB are eligible to apply for the one-time funding. Potential application scenarios include: 

Option 1: Public health laboratories that currently perform pDST for rifampin using 7H10 Middlebrook and/or MGIT and would like to evaluate the updated WHO CC of 0.5 mg/L. 

Option 2: Public health laboratories that currently perform first-line DST for MTB and would like to evaluate a FQ phenotypic or molecular susceptibility testing method(s) for MTB. 

Note: Laboratories may apply for both Option 1 and Option 2, but each option will be evaluated separately. 


Anticipated RF​​P Schedule ​

August 29, 2023 RFP Issued 

September 6, 2023 Informational Teleconference (register here​)

September 15, 2023 Required Letter of Intent Due to APHL (see below) 

October 13, 2023 RFP Responses Due 

October 27, 2023 Proposal Review Completed 

November 1-3, 2023 Follow-Up Interviews and Updated Proposals Due (if needed) 

November 10, 2023 Final Review Completed and Awardees Selected 

December 1, 2023 Estimated Contract Start Date 


APHL will communicate any modification to this anticipated schedule on APHL’s procurement website (www.aphl.org/rfp) and via an email blast to public health laboratories. 

Final Response ​

APHL must receive complete responses by 11:59 pm EDT on October 13, 2023. Please see Proposal-Required Submissions section for items that must be included in the completed proposal. Applicants may send proposals via email to Sarah.buss@aphl.org with a copy to infectious.diseases@aphl.org. 

APHL will send an email acknowledging the receipt of your application; if you do not receive an acknowledgement within two business days, please email the RFP point of contact above to confirm receipt. 

RFP Materials

APHL will post all RFP-related documents, current schedule information and answers to all submitted questions and clarifications on APHL's procurement site, The official RFP document will provide detailed information in regards to this request, please read it in its entirety.​

Questions and Answers

​​Where can I find the RFP application?

For evaluation of fluoroquinolone phenotypic testing does it matter which method of testing is used?

For option 2, can you evaluate both phenotypic and molecular methods if you are currently only doing growth-based (phenotypic) testing?

Is there any support for the protocols?

Is there a recommendation for which moxifloxacin concentrations to use for MGIT-based testing? 0.25 mg/L is the World Health Organization (WHO) critical concentration, should we be considering testing at a higher concentration if resistant to 0.25 mg/L?

Will there be isolates available to us for these evaluations?​


Would it be a good idea for us to apply for a support for the validation of FQs MICs on Sensititre under option 2

What would be your expectations for the deliverables at the end of RFP period? Would it be acceptable if we would have evaluated FQ MIC testing with Sensititre plates, but let’s say, haven’t yet completed the formal validation by June 2024?

Are indirect costs allowable in the budget?

Was the informational call recorded and is it able to be shared?